MPA
MCID: MCR088
MIFTS: 51

Microscopic Polyangiitis (MPA)

Categories: Bone diseases, Cardiovascular diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Microscopic Polyangiitis

MalaCards integrated aliases for Microscopic Polyangiitis:

Name: Microscopic Polyangiitis 20 58 36 17 32
Microscopic Polyarteritis 58 70
Micropolyangiitis 58
Mpa 58

Characteristics:

Orphanet epidemiological data:

58
microscopic polyangiitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Germany),1-9/1000000 (Norway),1-9/100000 (United Kingdom),1-9/100000 (Germany),1-9/100000 (Australia),1-9/100000 (Japan),1-9/100000 (Kuwait),1-9/1000000 (Canada),1-9/100000 (Greece),1-9/1000000 (Lithuania),1-9/100000 (Sweden); Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare circulatory system diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases


Summaries for Microscopic Polyangiitis

KEGG : 36 Microscopic polyangiitis (MPA) is an idiopathic autoimmune disease characterized by systemic vasculitis. MPA predominantly affects small-calibre blood vessels and is associated with the presence of antineutrophil cytoplasmic autoantibodies (ANCA). The association with ANCAs originally defined the group of ANCA-associated vasculitides, comprising granulomatosis with polyangitis (GPA, formerly known as Wegener granulomatosis) [DS:H01655], microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly known as Churg-Strauss syndrome) [DS:H01468], which have different frequencies of ANCA-positivity. ANCA in MPA are predominantly directed against myeloperoxidase (MPO-ANCA) but may, in a minority of patients, be directed against proteinase 3 (PR3-ANCA). Not all patients, however, have ANCA. MPA is clinically characterized by small-vessel vasculitis primarily affecting the kidneys and the lungs but other organs may be involved as well. Renal involvement, which can be the only manifestation, is clinically apparent as rapidly progressive glomerulonephritis and histopathologically as pauci-immune necrotizing and crescentic glomerulonephritis. Diagnosis is mainly established by clinical manifestations, computed tomography (TC), ANCA antibody detection, and renal and pulmonary biopsy. The introduction of aggressive immunosuppressive treatment has substantially improved the prognosis. The standardized therapeutic regimen is based on cyclophosphamide and corticosteroids. Using this regimen, remission can be achieved in most of the patients. Rituximab may represent an important alternative to cyclophosphamide for patients who may not respond adequately to antimetabolite therapies.

MalaCards based summary : Microscopic Polyangiitis, also known as microscopic polyarteritis, is related to polyarteritis nodosa and churg-strauss syndrome. An important gene associated with Microscopic Polyangiitis is HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1), and among its related pathways/superpathways are Innate Immune System and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. The drugs alemtuzumab and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, endothelial and heart, and related phenotypes are renal insufficiency and fever

GARD : 20 Microscopic polyangiitis (MPA) is a disorder that causes blood vessel inflammation ( vasculitis ), which can lead to organ damage. The kidneys, lungs, nerves, skin, and joints are the most commonly affected areas of the body. MPA is diagnosed in people of all ages, all ethnicities, and both genders. The cause of this disorder is unknown.

Wikipedia : 73 Microscopic polyangiitis is an ill-defined autoimmune disease characterized by a systemic, pauci-immune,... more...

Related Diseases for Microscopic Polyangiitis

Diseases related to Microscopic Polyangiitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 390)
# Related Disease Score Top Affiliating Genes
1 polyarteritis nodosa 31.2 MPO HLA-DRB1
2 churg-strauss syndrome 31.1 MPO HLA-DRB1
3 granulomatosis with polyangiitis 30.8 MPO FCGR3B
4 temporal arteritis 30.4 MPO HLA-DRB1
5 systemic autoimmune disease 29.9 FCGR3A FCGR2B
6 central nervous system vasculitis 29.9 MPO HLA-DRB1
7 sclerosing cholangitis 29.8 MPO HLA-DRB1
8 hypersensitivity vasculitis 29.8 MPO FCGR3B
9 cholangitis 29.8 MPO HLA-DRB1
10 peritonitis 29.8 MPO FCGR3B
11 takayasu arteritis 29.6 HLA-DRB1 FCGR3A FCGR2A
12 neutropenia 29.5 MPO FCGR3B FCGR3A
13 kawasaki disease 29.5 FCGR2B FCGR2A
14 thrombocytopenic purpura, autoimmune 29.4 HLA-DRB1 FCGR2B FCGR2A
15 goodpasture syndrome 29.3 MPO HLA-DRB1 FCGR2B FCGR2A
16 cryptococcosis 29.2 FCGR3B FCGR3A FCGR2A
17 bacterial infectious disease 29.1 FCGR3B FCGR3A FCGR2A
18 autoimmune disease 28.8 MPO HLA-DRB1 FCGR3B FCGR3A FCGR2B FCGR2A
19 lupus erythematosus 28.5 HLA-DRB1 FCGR3B FCGR3A FCGR2B FCGR2A
20 rheumatoid arthritis 28.3 MPO HLA-DRB1 FCGR3B FCGR3A FCGR2B FCGR2A
21 systemic lupus erythematosus 27.9 MPO HLA-DRB1 FCGR3B FCGR3A FCGR2B FCGR2A
22 vasculitis 11.4
23 anca-associated vasculitis 11.3
24 glomerulonephritis 10.9
25 crescentic glomerulonephritis 10.7
26 rapidly progressive glomerulonephritis 10.6
27 allergic angiitis 10.6
28 pulmonary fibrosis 10.6
29 proteinuria, chronic benign 10.5
30 respiratory failure 10.5
31 purpura 10.5
32 lung disease 10.5
33 interstitial lung disease 10.5
34 end stage renal disease 10.5
35 mononeuritis multiplex 10.5
36 diffuse alveolar hemorrhage 10.5
37 peripheral nervous system disease 10.5
38 neuropathy 10.4
39 acute kidney failure 10.4
40 fibrosis of extraocular muscles, congenital, 1 10.4
41 endometrial cancer 10.3
42 exanthem 10.3
43 aneurysm 10.3
44 pulmonary fibrosis, idiopathic 10.3
45 scleroderma, familial progressive 10.3
46 breast cancer 10.3
47 silicosis 10.3
48 pneumonia 10.3
49 toxoplasmosis 10.2
50 bronchiectasis 10.2

Graphical network of the top 20 diseases related to Microscopic Polyangiitis:



Diseases related to Microscopic Polyangiitis

Symptoms & Phenotypes for Microscopic Polyangiitis

Human phenotypes related to Microscopic Polyangiitis:

58 31 (show all 37)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0000083
2 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
3 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
4 hematuria 58 31 hallmark (90%) Very frequent (99-80%) HP:0000790
5 glomerulopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0100820
6 hemoptysis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002105
7 erythema 58 31 hallmark (90%) Very frequent (99-80%) HP:0010783
8 skin rash 58 31 hallmark (90%) Very frequent (99-80%) HP:0000988
9 vasculitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002633
10 oliguria 58 31 hallmark (90%) Very frequent (99-80%) HP:0100520
11 nausea and vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002017
12 venous thrombosis 58 31 frequent (33%) Frequent (79-30%) HP:0004936
13 skin ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0200042
14 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
15 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
16 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
17 gastrointestinal hemorrhage 58 31 frequent (33%) Frequent (79-30%) HP:0002239
18 subcutaneous hemorrhage 58 31 frequent (33%) Frequent (79-30%) HP:0001933
19 gastrointestinal infarctions 58 31 frequent (33%) Frequent (79-30%) HP:0005244
20 diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002014
21 peritonitis 58 31 frequent (33%) Frequent (79-30%) HP:0002586
22 arthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001369
23 sinusitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000246
24 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
25 abnormal retinal vascular morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0008046
26 subcutaneous nodule 58 31 occasional (7.5%) Occasional (29-5%) HP:0001482
27 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
28 uveitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000554
29 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
30 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
31 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
32 cutis marmorata 58 31 occasional (7.5%) Occasional (29-5%) HP:0000965
33 gangrene 58 31 occasional (7.5%) Occasional (29-5%) HP:0100758
34 pancreatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001733
35 episcleritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100534
36 peripheral neuropathy 58 Occasional (29-5%)
37 increased inflammatory response 58 Very frequent (99-80%)

Drugs & Therapeutics for Microscopic Polyangiitis

Drugs for Microscopic Polyangiitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 4 216503-57-0
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Azathioprine Approved Phase 4 446-86-6 2265
4
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
7
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
8
Povidone Approved Phase 4 9003-39-8 131751496
9
Hydroxychloroquine Approved Phase 4 118-42-3 3652
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11 Alkylating Agents Phase 4
12 Antibiotics, Antitubercular Phase 4
13 Immunosuppressive Agents Phase 4
14 Anti-Bacterial Agents Phase 4
15 Antitubercular Agents Phase 4
16 Antimetabolites Phase 4
17 Dermatologic Agents Phase 4
18 Vitamin B9 Phase 4
19 Folic Acid Antagonists Phase 4
20 Vitamin B Complex Phase 4
21 Folate Phase 4
22 Anti-Infective Agents Phase 4
23 Antimalarials Phase 4
24 Antiparasitic Agents Phase 4
25 Antiprotozoal Agents Phase 4
26 Immunologic Factors Phase 4
27 Antirheumatic Agents Phase 4
28 Antineoplastic Agents, Immunological Phase 4
29 Tin Fluorides Phase 4
30
belimumab Approved Phase 3 356547-88-1 5957 10451420
31
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
32
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
33
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
34
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
35
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
36
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
37
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
38 Plasma Substitutes Phase 3
39 Neuroprotective Agents Phase 2, Phase 3
40 Gastrointestinal Agents Phase 2, Phase 3
41 Methylprednisolone Acetate Phase 2, Phase 3
42 glucocorticoids Phase 2, Phase 3
43 Hormones Phase 2, Phase 3
44 Antineoplastic Agents, Hormonal Phase 2, Phase 3
45 Hormone Antagonists Phase 2, Phase 3
46 Antiemetics Phase 2, Phase 3
47 Anti-Inflammatory Agents Phase 2, Phase 3
48 Protective Agents Phase 2, Phase 3
49 Antibodies Phase 3
50 Immunoglobulins Phase 3

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
2 Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy Unknown status NCT01405807 Phase 4 Alemtuzumab
3 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
4 Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
5 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Recruiting NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
6 Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial Recruiting NCT04316494 Phase 4 Hydroxychloroquine;Placebo
7 Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial Active, not recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
8 Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
9 Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
10 An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis Completed NCT01697267 Phase 3 Azathioprine
11 Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
12 A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT01663623 Phase 3 Azathioprine
13 Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
14 Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial Completed NCT00987389 Phase 3 Glucocorticoids [Standard Dose];Glucocorticoids [Reduced Dose]
15 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
16 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
17 Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Not yet recruiting NCT03920722 Phase 3 Rituximab;placebo
18 Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener's Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
19 Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
20 Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
21 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial. Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
22 A Phase IIA, International, Multicenter, Open-label, Uncontrolled Study to Evaluate The Safety And Pharmacokinetics of 4 × 375 mg/m2 Intravenous Rituximab in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed NCT01750697 Phase 2 Rituximab
23 Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
24 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
25 A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Active, not recruiting NCT03895801 Phase 2 IFX-1;Placebo-IFX-1;Glucocorticoid (GC);Placebo-Glucocorticoid (Placebo-GC)
26 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Efficacy and Safety Study of IFX-1 in Add-On to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Active, not recruiting NCT03712345 Phase 2 IFX-1;IFX-1;Placebo
27 A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis Withdrawn NCT01598857 Phase 2 Blisibimod;Placebo
28 A Pilot Study of Mycophenolate Mofetil (MMF) in Patients With p-ANCA Microscopic Polyangiitis and Mild to Moderate Renal Dysfunction. Completed NCT00405860 Phase 1 CellCept (mycophenolate mofetil)
29 ACR/EULAR Endorsed Study to Develop New Diagnostic and Classification Criteria for Primary Systemic Vasculitis Unknown status NCT01066208
30 Cohort Study of Chinese Patients With Pulmonary Vasculitis Unknown status NCT02126098
31 A Qualitative Study Using Interviews With Patients Who Have Anti-neutrophil Cytoplasm Antibody (ANCA) Associated Vasculitis, to Develop a Patient Reported Outcome (PRO) Measure Unknown status NCT01729624
32 Prospective, Observational Safety Study of Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Treated With Rituximab Completed NCT01613599 Rituximab
33 Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies Completed NCT00307593 Infliximab;Rituximab
34 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
35 Impact of Vasculitis on Employment and Income. An Online Survey of Participants in the VCRC Patient Contact Registry Completed NCT02476292
36 Educational Needs of Patients With Systemic Vasculitis- an International Survey Completed NCT02190929
37 VCRC Validation of Patient-Reported Diagnostic Data Completed NCT02190942
38 The Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
39 Illness Perception, Fatigue, and Function in Systemic Vasculitis (The VCRC Vasculitis Perception (VIP) Study) Completed NCT02190916
40 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
41 Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis Recruiting NCT03698071
42 VCRC Tissue Biorepository Collection Protocol Recruiting NCT02967068
43 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
44 The Vasculitis Pregnancy Registry (V-PREG) Recruiting NCT02593565
45 A Local Interventional Study in a Cohort of Patients With GPA, MPA and EGPA (PART 2 of "Vitamin D Status in ANCA-associated Vasculitis: Analysis of RDCRN-VCRC and Local Clinic Cohorts of Patients With GPA, MPA and EGPA") Recruiting NCT04280601
46 Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes Recruiting NCT02006134
47 Determining Disease Activity Biomarkers in Individuals With Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis Active, not recruiting NCT00315393
48 VCRC Genetic Repository One-Time DNA Protocol Active, not recruiting NCT01241305
49 Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis : a Predictive Factor of Clinical Outcome? (MONITUX) Terminated NCT02474888
50 Rituximab for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (RAVE) Long-Term Follow-Up Study Terminated NCT01586858

Search NIH Clinical Center for Microscopic Polyangiitis

Genetic Tests for Microscopic Polyangiitis

Anatomical Context for Microscopic Polyangiitis

MalaCards organs/tissues related to Microscopic Polyangiitis:

40
Neutrophil, Endothelial, Heart, T Cells, Bone Marrow, Spinal Cord, Lung

Publications for Microscopic Polyangiitis

Articles related to Microscopic Polyangiitis:

(show top 50) (show all 1909)
# Title Authors PMID Year
1
A proposed role of neutrophil extracellular traps and their interplay with fibroblasts in ANCA-associated vasculitis lung fibrosis. 61
33609801 2021
2
De novo collapsing glomerulopathy in a pediatric kidney transplant recipient with COVID-19 infection. 61
33773007 2021
3
Rapidly worsening pneumonia in a middle-aged woman: a rare diagnosis and a crucial management decision. 61
33789859 2021
4
[Use of new diagnostic criteria for reclassification of polyarteritis nodosa]. 61
33663173 2021
5
Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody. 61
33726733 2021
6
Altered follicular regulatory T (Tfr) and helper T (Tfh) cell subsets are associated with auto-antibody levels in microscopic polyangiitis patients. 61
33764509 2021
7
Immunohistochemical detection of citrullinated histone H3-positive neutrophils is useful for identifying active glomerular and interstitial lesions in antineutrophil cytoplasmic antibody-associated vasculitis. 61
32956514 2021
8
ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies. 61
33744916 2021
9
Association between body mass index and severe infection in older adults with microscopic polyangiitis: a retrospective cohort in Japan. 61
33750328 2021
10
Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. 61
33021335 2021
11
Vascular endothelial growth factor (VEGF)-A and VEGF-A165b are associated with time to remission of granulomatosis with polyangiitis in a nationwide Japanese prospective cohort study. 61
33081494 2021
12
Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta-Analysis of Benefits and Harms of Common Treatments. 61
33590973 2021
13
Usefulness of tissue inhibitor of metalloproteinase 1 as a predictor of sustained remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis. 61
33743769 2021
14
Systematic Histological Scoring Reveals More Prominent Interstitial Inflammation in Myeloperoxidase-ANCA Compared to Proteinase 3-ANCA Glomerulonephritis. 61
33809645 2021
15
Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients. 61
33741047 2021
16
Risk factors and outcomes of immune and non-immune causes of diffuse alveolar hemorrhage: a tertiary-care academic single-center experience. 61
33782747 2021
17
The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies. 61
33476813 2021
18
Pulmonary Involvement in Primary Systemic Vasculitides. 61
33788906 2021
19
Serum chitinase-3-like 1 protein is a useful biomarker to assess disease activity in ANCA-associated vasculitis: an observational study. 61
33685523 2021
20
Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. 61
33675161 2021
21
Advances in the genomics of ANCA-associated vasculitis-a view from East Asia. 61
33686257 2021
22
[Cortisone-free rheumatology-Vasculitides]. 61
33709164 2021
23
Clinical significance of interstitial lung disease and its acute exacerbation in microscopic polyangiitis. 61
33571506 2021
24
Microscopic Polyangiitis Presenting with Splenic Infarction: A Case Report. 61
33572204 2021
25
Deep vein thrombosis: An unusual way of revealing microscopic polyangiitis. Deep vein thrombosis in microscopic polyangiitis. 61
33598213 2021
26
Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. 61
33523099 2021
27
Relapse rate and renal prognosis in ANCA-associated vasculitis according to long-term ANCA patterns. 61
33020895 2021
28
The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies. 61
33034910 2021
29
Muscle biopsy in anti-neutrophil cytoplasmic antibody-associated vasculitis: diagnostic yield depends on anti-neutrophil cytoplasmic antibody type, sex and neutrophil count. 61
32789447 2021
30
Polyangiitis overlap syndrome: a novel presentation of microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis. 61
33526532 2021
31
Cumulative incidence of femoral localized periosteal thickening (beaking) preceding atypical femoral fractures in patients with rheumatoid arthritis. 61
32885317 2021
32
Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan Otological Society. 61
32768313 2021
33
Sequential occurrence of microscopic polyangiitis and anti-glomerular basement membrane disease in a patient with small cell lung cancer: a case report. 61
33517889 2021
34
Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. 61
33512787 2021
35
Intramedullary lesion resection as an effective treatment of spinal cord microscopic polyangiitis: a case report. 61
33608757 2021
36
Fibrosis-5 predicts end-stage renal disease in patients with microscopic polyangiitis and granulomatosis with polyangiitis without substantial liver diseases. 61
33611672 2021
37
Kaposi sarcoma in anti-neutrophil cytoplasmic antibody-associated vasculitis: a case-based review. 61
33620515 2021
38
A case of intravascular large B-cell lymphoma with renal involvement presenting with elevated serum ANCA titers. 61
32776181 2021
39
Orbital Microscopic Polyangiitis With Secondary Angle Closure Due to Uveal Effusion. 61
32433349 2021
40
Slo-Mo anti-neutrophil cytoplasmic antibody-associated renal vasculitis. 61
33564403 2021
41
Evaluation of poor prognostic factors of respiratory related death in microscopic polyangiitis complicated by interstitial lung disease. 61
33452394 2021
42
CCL2 Produced by CD68+/CD163+ Macrophages as a Promising Clinical Biomarker of Microscopic Polyanigiitis-Interstitial Lung Disease. 61
33493350 2021
43
Comment on: Microscopic polyangiitis: clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry by Nguyen et al. 61
33025879 2021
44
Reply to the comment on: Microscopic polyangiitis: clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry by Nguyen et al. 61
33025896 2021
45
Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report. 61
32687015 2021
46
New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. 61
33501936 2021
47
ANCA-negative microscopic polyangiitis with diffuse alveolar hemorrhage masquerading as congestive heart failure. 61
33407881 2021
48
A Case of Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis Overlap Syndrome. 61
33505756 2021
49
Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome. 61
33564436 2021
50
Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis. 61
33446268 2021

Variations for Microscopic Polyangiitis

Expression for Microscopic Polyangiitis

Search GEO for disease gene expression data for Microscopic Polyangiitis.

Pathways for Microscopic Polyangiitis

Pathways related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 MPO HLA-DRB1 FCGR3B FCGR3A FCGR2B FCGR2A
2
Show member pathways
13.34 MPO HLA-DRB1 FCGR3B FCGR3A FCGR2A
3
Show member pathways
11.98 HLA-DRB1 FCGR3B FCGR3A FCGR2A
4 11.81 HLA-DRB1 FCGR3B FCGR3A FCGR2B FCGR2A
5 11.78 FCGR3B FCGR3A FCGR2B FCGR2A
6
Show member pathways
11.72 FCGR3B FCGR2B FCGR2A
7 11.61 FCGR3B FCGR3A FCGR2B FCGR2A
8 11.59 MPO FCGR2A
9 11.44 FCGR3B FCGR2A
10 11.38 FCGR3B FCGR3A FCGR2B FCGR2A
11 11.34 HLA-DRB1 FCGR3B FCGR3A FCGR2B FCGR2A
12 11.28 MPO HLA-DRB1 FCGR3B FCGR3A FCGR2B FCGR2A
13
Show member pathways
11.23 FCGR3A FCGR2A

GO Terms for Microscopic Polyangiitis

Cellular components related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule membrane GO:0030667 9.16 FCGR3B FCGR2A
2 external side of plasma membrane GO:0009897 9.13 HLA-DRB1 FCGR3A FCGR2B
3 integral component of plasma membrane GO:0005887 9.02 HLA-DRB1 FCGR3B FCGR3A FCGR2B FCGR2A

Biological processes related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.5 MPO FCGR3B FCGR2A
2 immune response GO:0006955 9.46 HLA-DRB1 FCGR3B FCGR3A FCGR2B
3 Fc-gamma receptor signaling pathway involved in phagocytosis GO:0038096 9.43 FCGR3A FCGR2B FCGR2A
4 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.37 HLA-DRB1 FCGR2B
5 cell surface receptor signaling pathway GO:0007166 9.26 FCGR3B FCGR3A FCGR2B FCGR2A
6 regulation of immune response GO:0050776 8.92 FCGR3B FCGR3A FCGR2B FCGR2A

Molecular functions related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.26 FCGR3B FCGR3A FCGR2B FCGR2A
2 IgG binding GO:0019864 8.92 FCGR3B FCGR3A FCGR2B FCGR2A

Sources for Microscopic Polyangiitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....